Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022
By LabMedica International staff writers Posted on 26 Apr 2022 |
Abbott (Lake Forest, IL, USA) participated in ECCMID 2022 where it highlighted its range of rapid diagnostic platforms that complement centralized RT-PCR testing as well as empowers labs to efficiently and cost-effectively extend their impact throughout hospitals.
Abbott’s product portfolio exhibited at ECCMID 2022 included ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The company’s ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing healthcare professionals to make effective clinical decisions sooner. Abbott demonstrated its Panbio COVID-19 Ag Rapid Test Device that can identify potentially contagious patients with or without symptoms in 15 minutes alongside its Panbio COVID-19 IgG/IgM Rapid Test Device for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood.
In addition, Abbott demonstrated its Afinion CRP rapid in vitro diagnostic test for the quantitative determination of C-reactive protein (CRP) in human blood in three minutes. Afinion CRP helps reduce diagnostic uncertainty and guides antibiotic decision-making during the patient’s visit. A significantly increased CRP result may indicate the need for immediate antibiotic treatment. CRP Point of care testing has been shown to reduce antibiotic prescribing by more than 60% if combined with communication training for general practitioners. The test runs on Abbott’s Afinion2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care. With the Afinion System, there’s no need to send patients to the lab or spend time tracking down their results.
Related Links:
Abbott
Latest ECCMID 2022 News
- BD Presents Latest Automated Solutions to Combat Antimicrobial Resistance at ECCMID 2022
- Boditech Presents Latest IVD Solutions at ECCMID 2022
- CerTest Presents VIASURE Complete Solution for Improved Molecular Diagnostic Workflow
- BioVendor Presents Its Portfolio of IVD Products and Technologies for Lab Automation
- Bio-Rad Exhibits Complete Infectious Disease Testing Portfolio at ECCMID 2022
- Siemens Presents Its Full Portfolio of COVID-19 Testing Solutions at ECCMID 2022
- MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection
- Seegene Showcases All-in-One Platform for Molecular Diagnostic Testing for Infectious Diseases
- Beckman Coulter Presents Virtual Showcase of MicroScan Microbiology Solutions
- Randox Presents Vivalytic Universal, Fully Automated All-in-One Solution for Molecular Diagnostics at ECCMID 2022
- Meridian Bioscience Exhibits Curian Immunofluorescent Testing Platform at ECCMID 2022
- Copan Showcases Fully Automated Solutions for Antibiotic Susceptibility Testing at ECCMID 2022
- Autobio Diagnostics Showcases Automated Microbial Identification and ID-AST Solutions at ECCMID 2022
- Altona Diagnostics Exhibits AltoStar Product Range at ECCMID 2022
- Alifax Presents First Automated System for Bacterial Culture and Susceptibility Testing at ECCMID 2022
- LumiraDx Demonstrates Use of LumiraDx Platform in Infectious Disease Testing at ECCMID 2022